Rhythm Pharmaceuticals Files Definitive Proxy Statement

TL;DR

RHYTHM PHARMACEUTICALS FILED PROXY STATEMENT - VOTE YOUR SHARES!

AI Summary

Rhythm Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEFA14A) on June 17, 2024. This filing is related to the company's annual meeting and likely concerns the election of directors and other corporate governance matters. The company is based in Boston, MA, and operates in the pharmaceutical preparations industry.

Why It Matters

This filing provides shareholders with crucial information regarding company governance and voting matters, impacting their ability to influence the company's direction.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEFA14A) for a public company, not indicating any immediate financial distress or significant operational change.

Key Numbers

• 001-38223 — SEC File Number (Identifies the company's registration with the SEC.)
• 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)

Key Players & Entities

• Rhythm Pharmaceuticals, Inc. (company) — Registrant
• 222 Berkeley Street, 12th Floor, Boston, MA 02116 (company) — Business and Mail Address
• 0001104659-24-072388 (dollar_amount) — Accession Number
• 20240617 (dollar_amount) — Filing Date

FAQ

Filing Documents

• tm2417471d2_defa14a.htm (DEFA14A) — 11KB
• 0001104659-24-072388.txt ( ) — 12KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12 Rhythm Pharmaceuticals, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Rhythm Pharmaceuticals, Inc. (the “Company”) today announced that its 2024 annual meeting of stockholders, originally scheduled for June 18, 2024, has been postponed to September 18, 2024 (as postponed, the “Annual Meeting”). The Board has approved July 24, 2024 as the record date for the Annual Meeting. The Company intends to file updated proxy materials for the Annual Meeting with the Securities and Exchange Commission and mail such materials to stockholders of record as of the newly established record date. The postponement of the Annual Meeting is due solely to a technical error in the record date that was used to conduct the broker search for the June 18, 2024 annual meeting of stockholders. According to preliminary voting reports received by the Company, as of June 17, 2024, sufficient votes were received from stockholders on the record date used for the broker search to indicate that a quorum would have been achieved and each proposal to be presented at the meeting would have passed by a significant margin if that record date had been correct. The Board has determined to postpone the Annual Meeting and establish a new record for the Annual Meeting to ensure that all stockholders of record on the record date established by the Board receive the proxy materials. The Board has not made any changes to the proposals to be considered by stockholders at the Annual Meeting from the proposals disclosed in the Company’s definitive proxy statement filed on April 26, 2024. Any stockholder of the Company seeking to bring business before the Annual Meeting or to nominate a director must provide timely notice, as set forth in the Company’s Amended and Restated Bylaws (the “Bylaws”). Specifically, written notice of any proposed business or nomination must be received at the Company’s principal executive offices no later than June 27, 2024 (which is the tenth (10th) day following the date of this Current Report on Form 8-K). Any notice of proposed business or nomination must comply with the specific requirements set forth in the Bylaws. Under Rule 14a-8 of the Securities and Exchange Act, to submit a proposal for inclusion in our proxy statement for the Annual Meeting, stockholder proposals must be received at our principal executive offices no later than close of business on June 27, 2024.

View Full Filing

View this DEFA14A filing on SEC EDGAR